The estrogen receptor paradox in breast cancer: Association of high receptor concentrations with reduced overall survival

Breast Journal

Volumn 6, Issue 2, 2000, Pages 115-125

  Struse, Kerstin ^a   Audretsch, Werner ^b   Rezai, Mahdi ^b   Pott, Guido ^a   Bojar, Hans ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Munic Hospital of Düsseldorf   (Germany)

Author keywords

Breast cancer; Estrogen receptor; Prognosis

Indexed keywords

DNA; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE NEU; PLOIDY; PROGNOSIS;

EID: 0033996443     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2000.99060.x     Document Type: Article

References (45)

1. Thorpe S, Christensen IJ, Bruun Rasmussen B, Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. EurJ Cancer 1993;29A:971-77.
2. Allegra JC, Lippman M, Simon R, et al. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 1979;63:1271-77.
3. Knight WA, Livingston RB, Gregory EJ. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977;37:4669-71.
4. Knight WA, Livingston RB, Gregory EJ, Walder AI, McGuire WL, Murphy A. Absent estrogen receptor and decreased survival in human breast cancer. Proc AACR ASCO 1978.
5. Nicholson RI, Campbell FC, Blarney RW, Elston CW, George D, Griffiths K. Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem 1981;15:193-99.
6. Fisher B, Redmond CK, Wickerham DL, Rockette HE, Brown A. Relation of estrogen and/or progesterone receptor content in breast cancer to patient outcome following adjuvant therapy. Breast Cancer Res Treat 1983;3:335-64.
7. Howell A, Harland RNL, Bramwell VHC, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984;1:588-91.
8. Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer: technology, biology and clinical significance. Acta Oncol 1988;27:1-19.
9. 3 receptor in breast cancer and relationship to prognosis. Cancer Res 1991;51:239-44.
10. Molino A, Turazza M, Bonetti A, et al. Estrogen and progesterone receptors in breast cancer: correlation with clinical and pathological features and with prognosis. Oncology 1992;49:82-88.
11. Rudan I, Skoric T, Rudan N. Breast cancer prognosis. Prognostic factors in patients with node-negative breast cancer. Acta Med Croatica 1994;48:159-63.
12. Andersen J. Determination of estrogen receptors in paraffin-embedded tissue, techniques and the value in breast cancer treatment. Acta Oncol 1992;31:611-27.
13. Tsangaris TN, Knox SM, Cheek JH. Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma. Cancer 1992;69:984-87.
14. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T, Gomez F. The Predictive value of estrogen and progesterone receptor concentrations on the clinical behavior of breast cancer in women. Cancer 1986;57:1171-80.
15. Menendez-Botet CJ, Schwartz MK. Estrogen and progesterone receptor proteins in patients with breast cancer. Adv Clin Chem 1993;30:185-225.
16. Andry G, Suciu S, Pratola D, et al. Relation between estrogen receptor concentration and clinical and histological factors. Their relative prognostic importance after radical mastectomy for primary breast cancer. Eur J Cancer Clin Oncol 1989; 25:319-29.
17. Collett K, Hartveit F, Skjaerven R, Maehle BO. Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status. J Clin Pathol 1996;49:920-25.
18. Winstanley J, Cooke T, George WD, et al. The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br J Cancer 1991;64:99-101.
19. Raemakers JMM, Beex LVAM, Koenders AJM, et al. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 1985;6:123-30.
20. Aamdal S, Bormer O, Jorgensen O, et al. Estrogen receptor and long-term prognosis in breast cancer. Cancer 1984; 53:2525-29.
21. Hahnel A, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer 1979;44: 671-75.
22. Howat JMT, Barnes DM, Harris M, Swindel R. The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer 1993;47:629-40.
23. Saez S, Cheix F, Asselain B. Prognostic value of estrogen and progesterone receptors in primary breast cancer. Breast Cancer Res Treat 1983;43:2985-90.
24. Kurebayashi J, Ishida T, Higashi Y, Suemasu K, Nomoto C, Yoshoda K. Prognostic significance of estrogen and progesterone receptors in primary operable breast cancer. Jpn J Clin Oncol 1990;20:271-80.
25. Shek LL, Godolphin W. Survival with breast cancer. The importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 1989;25:243-50.
26. Sauerbrei W, Hübner K, Schmoor C, Schumacher M. Validation of existing and development of new prognostic classification schemes in nodal negative breast cancer. Breast Cancer Res Treat 1997;42:149-63.
27. Sancho-Garnier H, Delarue JC, Mouriesse H, et al. Is the negative prognostic value of high oestrogen receptor levels in postmenopausal breast cancer due to a modified ER gene product? Eur J Cancer 1995;31:1851-55.
28. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980;16:1513-15.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;35:457-81.
30. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trial requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
31. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.
32. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. Am Stat Assoc 1979;77:829-36.
33. Goldhirsch A, Wood WC, Senn HJ, Click JH, Gelber RD. IXth International Consensus Conference on Primary Treatment of Breast Cancer. Recent Results Cancer Res 1996; 140:325-35.
34. Black R, Prescott R, Bers K, Hawkins A, Stewart H, Forrest P. Tumor cellularity, estrogen receptors and prognosis in breast cancer. Clin Oncol 1983;9:311-18.
35. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M, German Breast Cancer Study Group (GBSG). Modelling the effects of standard prognostic factors in node positive breast cancer. Br J Cancer 1999;79:1752-60.
36. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal cutpoints" in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
37. Gamulin S, Romic-Stojkovic R. Oestrogen and progesterone receptors in primary breast cancer: a population study. Eur J Cancer 1991;27:491-95.
38. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984;2: 1102-9.
39. Blanco G, Alavaikko M, Ojala A, et al. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients. Anticancer Res 1984;4:383-90.
40. Fernö M, Borg A, Johansson U, et al. Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples. A study with special reference to age diagnosis and stability of analyses. Acta Oncol 1990;29: 129-35.
41. May-Levin F, Guerinot G, Contesso J, Delarue C, Bohuon C. Etude des recepteurs cytosoliques oestrogenes et progestogenes dans les carcinomes mammaires. Int J Cancer 1977;19:789-95.
42. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: Are there age differentials? J Natl Cancer Inst Monogr 1994;16:35-42.
43. Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N. Systemically untreated patients with node negative primary breast cancer. Cancer Res 1987;47:6126-33.
44. Wilking N, Rutqvist LE, Nordenskjold B, Skoog L. Steroid receptor levels in breast cancer. Relationships with age and menopausal status. Acta Oncol 1989;28:807-10.
45. McCarty KS Jr, Silva JS, Cox EB, Leight GS, Wells SA Jr, McCarty KS Sr. Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann Surg 1983;197:123-27.